Identification of Genetic Factors that Modify Clinical Onset of Huntington’s DiseaseJong‐Min Lee, Richard H. Myers, Marcy E. MacDonald et al.|Cell|2015Cited by 671
CAG Repeat Not Polyglutamine Length Determines Timing of Huntington’s Disease OnsetJong‐Min Lee, Richard H. Myers, Kevin Correia et al.|Cell|2019Cited by 558
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging studyRalf Reilmann, Hope Heller, Andrew McGarry et al.|The Lancet Neurology|2018Cited by 108
Brain Regions Showing White Matter Loss in Huntington’s Disease Are Enriched for Synaptic and Metabolic GenesPeter McColgan, D. Crawfurd, Sarah Gregory et al.|Biological Psychiatry|2017Cited by 104
Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results from the Phase II, Double-blind, Placebo-controlled, Dose-Ranging Study, Pride-HD (P2.005)Karl Kieburtz, Michael R. Hayden, G. Bernhard Landwehrmeyer et al.|Neurology|2017Cited by 10